Global Urinary Tract Infection Therapeutics Market Size study & Forecast, by Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, and Other Drugs), by Indication (Complicated UTI, Uncomplicated UTI, and Oth

Global Urinary Tract Infection Therapeutics Market Size study & Forecast, by Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, and Other Drugs), by Indication (Complicated UTI, Uncomplicated UTI, and Other Indications), and Regional Analysis, 2022-2029

The global Urinary Tract Infection Therapeutics Market is valued at approximately USD 8.66 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 3 % over the forecast period 2022-2029. Urinary Tract Infection is one of the most common bacterial infections that occur majorly in women as compared to men. It affects the urinary tract. The Urinary Tract Infection Therapeutics market is expanding because of factors such as the rising growing prevalence of kidney stones and diabetes and the launch of combination drugs.

According to the World Health Organization 2019, diabetes claimed the lives of approximately 1.5 million people worldwide, Diabetes currently affects 537 million people worldwide, according to estimates. Projections show that by 2045, there will be 783 million diabetics worldwide. Whereas the rising geriatric population and growing R&D activities by market players create lucrative opportunities for the market. However, lack of awareness in developing countries hampers market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Urinary Tract Infection Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the increasing prevalence of kidney stones, and diabetes. , Also, North America is expected to grow with the highest CAGR during the forecast period, owing to factors such as increasing awareness towards UTIs, growing spending towards personal care, and growth activities by market players in the forecast period.

Major market players included in this report are:
AstraZeneca
Bayer AG
Cipla Inc.
GlaxoSmithKline PLC
Shionogi & Co. Ltd
Novartis AG
Pfizer
Merck & Co. Inc
Bristol-Myers Squibb Company
Almirall SA

Recent Developments in the Market:
 In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI) caused by susceptible microorganisms, including pyelonephritis.
 In September 2021, Biapenem was introduced by BDR Pharma, one of India’s leading generic pharmaceutical companies, to treat patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.

Global Urinary Tract Infection Therapeutics Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drug, Indication, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drug:
Penicillin and Combinations
Quinolones
Cephalosporin
Azoles and Amphotericin B
Nitrofurans
Other Drugs

By Indication:
Complicated UTI
Uncomplicated UTI
Other Indications

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

AstraZeneca
Bayer AG
Cipla Inc.
GlaxoSmithKline PLC
Shionogi & Co. Ltd
Novartis AG
Pfizer
Merck & Co. Inc
Bristol-Myers Squibb Company
Almirall SA

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.